CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increased efficiency in the manufacturing process
4.1.2. Support from regulatory authorities for the implementation of continuous
manufacturing
4.1.3. A cost-effective approach for pharmaceutical manufacturing
4.1.4. Safer production and increased FDA activities
4.1.5. Advantages over the batch manufacturing
4.2. Market Restraints & Challenges
4.2.1. Regulatory Challenges
4.2.2. Concerns related to cleaning validation in continuous manufacturing
4.2.3. Lack of technical clarity and difficulties in adoption
4.3. Market Opportunities
4.3.1. Growth in generic manufacturing
4.3.2. Industry and academia collaborations
CHAPTER 5. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING
MARKET – BY PRODUCT
5.1. Integrated Systems
5.2. Controls
5.3. Semi-Continuous Systems
5.3.1. Continuous Granulators
5.3.2. Continuous Blenders
5.3.3. Continuous Compressors
5.3.4. Continuous Coaters
5.3.5. Continuous Dryers
5.3.6. Others
CHAPTER 6. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING
MARKET – BY APPLICATION
6.1. End Product Manufacturing
6.1.1. Solid Dosage Manufacturing
6.1.2. Liquid Dosage Manufacturing
6.2. API Manufacturing
CHAPTER 7. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING
MARKET – BY END USER
7.1. R&D Departments
7.1.1. Contract Research Organizations
7.1.2. Research Institutes
7.2. Full-Scale Manufacturing Companies
7.2.1. Pharmaceutical Companies
7.2.2. Contract Manufacturing Organizations
CHAPTER 8. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING
MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING
MARKET - COMPANY PROFILES
9.1. Siemens AG
9.2. GEA Group
9.3. SK Biotech Co., Ltd
9.4. CONTINUUS Pharmaceuticals
9.5. Glatt GmbH
9.6. KORSCH AG
9.7. Scott Equipment Company
9.8. Thermo Fisher Scientific, Inc.
9.9. L.B. Bohle Maschinen + Verfahren GmbH
9.10. Bosch Packaging Technology
9.11. Baker Perkins Ltd
9.12. Sturtevant Inc.
9.13. Munson Machinery Company, Inc.
9.14. Hosokawa Micron Corporation
9.15. Coperion GmbH
CHAPTER 10. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING
MARKET - COMPETITIVE LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
